HSP90AA1 and gastrointestinal stromal tumor: Notably, the Hsp90 inhibitor pimitespib (Taiho Pharmaceutical Co. Ltd.)received approval in Japan in 2022 for the treatment of gastrointestinal stromal tumour (GIST) that has progressed after chemotherapy (Doi et al. 2024).